搜索到 1000 条关于 ㎂밍키넷▥rCF928˛tOP∈기모찌닷컴새주소㎈밤에만넷최신주소㎮천사티비도메인㎫삼다수 최신주소⊂딸블러새주소 的文章

2012.09.19 2nd Asia-Pacific Osteoporosis and Bone Meeting

会议简介 WelcomeThe Presidents of IOF and ANZBMS along with the Local Organising Committee are pleased to invite you to participate in the IOF Regionals - 2nd Asia-Pacific Osteoporosis and Bone Meeting being held in conjunction with the ANZBMS Annual Scientific Meeting and JSBMR in September 4-8, 2011.The Asia-Pacific region is the largest growth market in the world in the bone field. As revealed by the IOF Asian Audit in 2009, it is anticipated that by 2050 more than 50% of all osteoporotic fractures will occur in Asia.With an active Asia-Pacific Office and 28 member societies from the Region,? IOF Regionals provide the first and only? annual opportunity for a truly Regional Meeting to occur in the Asia-Pacific Region.? IOF Meetings focus on clinical treatment of osteoporosis as well as cutting edge science in the field. ANZBMS meetings are the peak Bone and Mineral professional events in the Australian and New Zealand region and JSBMR serves the entire Japanese community with annual scientific meetings in the area of bone and mineral research.The Meeting format includes plenary sessions, abstract presentations, poster presentations and viewing, Meet-the-Expert sessions, satellite symposia, award presentations, workshops and several social events.We hope to see you there!John A. Kanis,
President - International Osteoporosis FoundationRebecca Mason,
President - Australian and New Zealand Bone & Mineral Society
Program ? ?
Please see below for a draft program at a glance and preliminary seminar topics and associated titles. Please keep posted for more program details.PROGRAM AT A GLANCE - Please click here for a downloadable program at a glanceSEMINAR TOPICS
  • Biomechanics and Bone Measurement
  • Mark Forwood , "Why bones fail: structure and mechanics"
  • Ego Seeman , "Measuring microarchitecture"
  • Clinical Management of Osteoporosis I
  • Hiroshi Hagino , "Incidence and prevention of second hip fracture in Japan"
  • John Kanis , "To BMD or not to BMD?
  • Markus Seibel , "Fracture liaison services"
  • Clinical Osteoporosis Management II
  • Jacqui Center , "Osteoporosis Management and Mortality"
  • Toshio Matsumoto , "New strategies for treatment of osteoporosis"
  • Philip Sambrook , "Osteoporosis:? what should we measure, what should we check, whom should we treat, and with what?"
  • Fracture Risk Algorithms: Soothsaying or Science?
  • Emma Duncan , "Genetics, bones and fracture"
  • John Kanis , Getting to Grips with FRAX: how it really works
  • Male Osteoporosis
  • Shigeaki Kato , "Estrogens, androgens and bone"
  • Eric Orwoll , "Osteoporosis in men"
  • Malignancy and Bone
  • Cory Xian , "Mechanisms and prevention for cancer chemotherapy-induced bone defects"
  • Toshio Yoneda , "Bone pain associated with cancer metastasis to bone"
  • Andrew Zannetino , "Myeloma and bone"
  • Non-Canonical Bone
  • Paul Baldock , "Bones and brains"
  • Caryl Nowson , "Bones and salt: the renin/angiotensin/aldosterone axis in bone"
  • Matthew Warman , "LRP5, serotonin and bone"
  • Osteoclasts
  • Natalie Sims , "Osteoblastic support of osteoclasts"
  • Nao Takahashi , "Quiescent osteoclast precursors"
  • Sanuo Takeshita , "Couplin"
  • Sakae Tanaka , "Regulation of activity and apoptosis of osteoclasts"
  • Osteoporosis in Oceania / Asia Pacific Region
  • Cyrus Cooper, "Secular trends in fracture incidence: Why are fractures increasing in Asia but falling in the West?"
  • Edith Lau , "Strategies for fracture prevention in Asia - where do we go from here?"
  • Ambrish Mithal , "Strategies to overcome epidemic of Vitamin D deficiency in Asia"
  • Paediatric Bone Disease
  • Christopher Cowell , "Measuring a growing skeleton, and the effect of ethnicity on bone and body composition"?
  • Keiichi Ozono , "Osteoporosis and Osteopetrosis in the young"
  • Tania Winzenberg , "Nutrition and bone in children"
  • Paget''s Disease
  • Tim Cundy , "The epidemiology of Paget''s disease"
  • Stuart Ralston , "The genetics of Paget''s disease"
  • Rheumatology and Bone
  • Steven Goldring , "Inflammation and bone resorption in Rheumatoid Arthritis"
  • Hiroshi Takayanagi , "Osteoimmunology"
  • Gethin Thomas , "Inflammation and bone formation in Ankylosing Spondylitis"
  • Skeletal Dysplasias
  • Seiji Fukumoto , "Hypophosphataemia and FGF23"
  • Matthew Warman , "Mouse models for Skeletal Dysplasias"
  • Andreas Zankl , "Skeletal dysplasias: a new approach"
  • The Effects of Ageing
  • Neil Binkley , "Sarcopaenia and ageing"
  • David Scott , "Sarcopaenia and Vitamin D"
  • Therapeutics in Osteoporosis: Controversies
  • Peter Ebeling , "The perils and pitfalls of antiresorptives"
  • Satoshi Mori , "Fracture healing- tissue changes with bisphosphonates"
  • Alvin Ng , "Atypical Subtrochanteric and Diaphyseal Femoral Fractures - What We Know and What We Don''t"
  • Speaker to be confirmed , "The positives of bisphosphonates"
  • Workshop on Bone Regeneration
  • Simon Cool , "Stem cells and fracture repair"
  • Yunfeng Lin , "Adipose Stem Cells and Craniofacial Regeneration"
  • Hala Zreiqat , "A basis for building bone:? novel nanocomposite scaffolds for new bone growth"
2017 年 6 月 JCO 在线肿瘤研究进展速递

2017.07.13 2017 年 6 月 JCO 在线肿瘤研究进展速递

TOP2A 正常乳腺癌患者的 DBCG 07-READ 研究:多中心开放标签 III 期研究中,2012 名早期 TOP2A 正常的乳腺癌患者随机接受 6 周期...,无远处转移生存,死亡率都没有显著差异。3 级肿瘤从 DC 获益更多,1~2 级肿瘤从 EC-D 获益更多。证实早期 TOP2A 正常乳腺癌患者从辅助蒽环类药物
非 ST 段抬高型心肌梗死  侵入性治疗越早越好

2016.11.28 非 ST 段抬高型心肌梗死 侵入性治疗越早越好

257(24%)名患者再次进行了血运重建。随访期间,侵入性治疗组中出现 928 个事件;非侵入性治疗组中出现 1040 个事件 。两组患者的基线治疗未见明显
一表轻松搞定:那些不宜与盐/糖水配伍的药物

2016.11.11 一表轻松搞定:那些不宜与盐/糖水配伍的药物

: 中国医药科技出版社,2010: 928-1012.2. 陈新谦. 新编药物学 [M]. 第 16 版. 北京:人民卫生出版社.2008,86.3. 陶建. 常用

2015.01.18 iCare CRM-医疗器械行业应用经验分享会

pm-4:30pm- 会议地点:上海市徐汇区柳州路928号百丽国际广场1003室 (近中山西路吴中路,宜山路地铁站)- 主题介绍: iCare CRM是基于
炎症基因表达改变或参与T1DM及其并发症的发生

2013.06.06 炎症基因表达改变或参与T1DM及其并发症的发生

Care)杂志上。研究人员采用高通量实时RT-PCR法验证928名T1D患者和922名对照者外周血单核细胞(PBMCs)中的基因表达变化
Intensive Care Med:羟乙基淀粉会增加成人急症患者肾脏替代治疗风险

2013.04.28 Intensive Care Med:羟乙基淀粉会增加成人急症患者肾脏替代治疗风险

)于2012年的3项大型试验的偏倚风险最低,这三项试验招募的患者占患者总数的77 %。6 % HES 130组4,691例患者中,928 (19.8 %)例患者
武汉成医药科技前沿技术聚集地,「国之重器」亮相健博会

2019.04.11 武汉成医药科技前沿技术聚集地,「国之重器」亮相健博会

;go.Top 新型未来CT、静脉麻醉药瑞马唑仑和口服靶向抗肿瘤药吡咯替尼正式亮相。发布会上,西门子医疗系统有限公司、江苏恒瑞医药股份有限公司作为代表企业,分别发布各自的全新产品。SOMATOMgo.Top 新型未来CT 采用集成化的诊断平台,不仅
丁香园独家专访沃芬公司副总裁 Gilles Castera:引领中国市场,满足用户需求

2018.06.13 丁香园独家专访沃芬公司副总裁 Gilles Castera:引领中国市场,满足用户需求

流水线,它整合了全球领先的全自动凝血分析仪 ACL TOP 700 LAS、市场上最完善的凝血检测菜单 HemosIL、专为凝血实验室设计的智能数据管理系统... 月底,新一代全自动凝血分析仪 ACL TOP Family 50 系列产品即将来到中国,这是全球第一个具有项目特异性分析前样本质量核查功能的凝血分析仪,被誉为

2017.08.15 IDMF 第二届中国国际药品微生物高峰论坛

——制药企业质量负责人(国内大型)Quality head from top domestic company4、16:10-17:00无菌工艺关键... top 500 company17:00-17:20 演讲专家集体交流答疑 Experts Answering Questions17
上一页 1 2 3 ... 40 41 42 ... 48 49 50 下一页 到第